Shanthi Mogali
Assistant Professor of PsychiatryDownloadHi-Res Photo
Cards
Appointments
Psychiatry
Primary
Additional Titles
Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry
Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Contact Info
Appointments
Psychiatry
Primary
Additional Titles
Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry
Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Contact Info
Appointments
Psychiatry
Primary
Additional Titles
Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry
Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Contact Info
About
Titles
Assistant Professor of Psychiatry
Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry; Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Appointments
Psychiatry
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Non Degree Program
- Columbia University, Addiction Psychiatry (2011)
- Non Degree Program
- Emory University School of Medicine, General Psychiatry
- MD
- Meharry Medical College (2005)
- BA
- Fisk University
Research
Overview
As a fellow, Dr. Mogali received pilot funding for her study examining microglial inhibitors in opioid abusers (manuscript in preparation for publication) and completed a secondary analysis of data collected to determine demographic factors of patients that may predict completion of a rapid naltrexone detoxification. As an Instructor, Dr. Mogali co-authored a chapter on Treatment of Pain and Opioid Use in the textbook, "Research and Development of Opioid-Related Ligands" and co-authored a review article on combination drug use of opioids, benzodiazepine and alcohol. She received mentorship in opioid research in the human laboratory setting under Dr. Sandra Comer, Ph.D. Dr. Mogali served as the research psychiatrist for the opioid laboratory at Columbia University. Her research interests include medication development and opioid self-administration studies that may influence treatment of opioid use disorders.
Research at a Glance
Publications Timeline
A big-picture view of Shanthi Mogali's research output by year.
16Publications
793Citations
Publications
2022
The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects.
Jones JD, Mumtaz M, Vadhan NP, Martinez S, Pramanik S, Manubay J, Mogali S, Perez F, Castillo F, Kranzler HR, Comer SD. The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects. Behavioural Pharmacology 2022, 33: 255-265. PMID: 35438671, PMCID: PMC9149033, DOI: 10.1097/FBP.0000000000000671.Peer-Reviewed Original Research
2021
Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users
Mogali S, Askalsky P, Madera G, Jones JD, Comer SD. Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users. Pharmacology Biochemistry And Behavior 2021, 209: 173241. PMID: 34298029, PMCID: PMC8429209, DOI: 10.1016/j.pbb.2021.173241.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsAnalgesic effectRecreational opioid usersReceptor-selective agonistOpioid usersPreclinical studiesAbuse liabilityNew York State Psychiatric InstituteRelease of cytokinesPositive subjective effectsTetracycline antibiotic minocyclineYears of ageDouble-blind outpatient studyPositive subjective responsesGlial activationAcute administrationCertain medicationsHuman research volunteersOutpatient studyGlial cellsNon-treatment seekingSame dosesRewarding effectsOxycodoneDrug AdministrationMinocycline
2020
Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.
Brandt L, Jones JD, Martinez S, Manubay JM, Mogali S, Ramey T, Levin FR, Comer SD. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug And Alcohol Dependence 2020, 208: 107859. PMID: 31980285, PMCID: PMC7063580, DOI: 10.1016/j.drugalcdep.2020.107859.Peer-Reviewed Original Research
2019
Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone.
Jones JD, Mumtaz M, Manubay JM, Mogali S, Sherwin E, Martinez S, Comer SD. Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. Pharmacology, Biochemistry, And Behavior 2019, 186: 172778. PMID: 31493434, PMCID: PMC6801039, DOI: 10.1016/j.pbb.2019.172778.Peer-Reviewed Original Research
2018
The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety.
Jones JD, Bisaga A, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Madera G, Doernberg M, Comer SD. The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. Journal Of Psychoactive Drugs 2018, 50: 390-401. PMID: 30204554, PMCID: PMC6487639, DOI: 10.1080/02791072.2018.1508789.Peer-Reviewed Original Research
2017
Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential.
Jones JD, Comer SD, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Martinez S, Mumtaz M, Bisaga A. Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. Pharmacology, Biochemistry, And Behavior 2017, 163: 90-100. PMID: 29020601, PMCID: PMC5959043, DOI: 10.1016/j.pbb.2017.10.002.Peer-Reviewed Original ResearchAbuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.
Jones JD, Manubay JM, Mogali S, Metz VE, Madera G, Martinez S, Mumtaz M, Comer SD. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug And Alcohol Dependence 2017, 179: 362-369. PMID: 28844013, DOI: 10.1016/j.drugalcdep.2017.06.033.Peer-Reviewed Original ResearchEffects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence
Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G, Johnson KW, Comer SD. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 2017, 42: 1825-1832. PMID: 28393896, PMCID: PMC5520790, DOI: 10.1038/npp.2017.70.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEffect of ibudilastVisual analog scaleAnalgesic effectOpioid dependenceEffects of oxycodoneGlial cell activationOpioid use disorderTreatment of asthmaDrug Effects QuestionnaireRecent preclinical studiesCold pressor testNonselective phosphodiesterase inhibitorMaintenance doseOxycodone administrationAnalog scaleWithdrawal symptomsDrug likingHeroin cravingPressor testMale volunteersPreclinical studiesIbudilastPatient detoxificationUse disordersOxycodone
2015
The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users
Jones JD, Sullivan MA, Manubay JM, Mogali S, Metz VE, Ciccocioppo R, Comer SD. The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. Physiology & Behavior 2015, 159: 33-39. PMID: 26455893, PMCID: PMC5444321, DOI: 10.1016/j.physbeh.2015.10.006.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEffect of pioglitazoneAbuse liabilityOpioid usersOpioid agonist effectsGood drug effectEffects of opioidsAbility of pioglitazoneActivation of PPARγPrescription opioid abusersDose-dependent increaseAddictive-like responsePositive subjective responsesMaintenance doseDaily dosesOpioid abusersOpioid receptorsPain perceptionReceptor agonistAgonist effectsDrug effectsOxycodonePioglitazoneRespiratory rateOpioidsCognitive effectsAbuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.
Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addiction Biology 2015, 20: 784-98. PMID: 25060839, PMCID: PMC4305506, DOI: 10.1111/adb.12163.Peer-Reviewed Original Research